Description
The skeptic raised concerns about genome-wide off-target epigenetic changes, but no systematic long-term safety studies exist. This knowledge gap is critical for regulatory approval of epigenome editing therapies.
Source: Debate session sess_SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 (Analysis: SDA-2026-04-02-gap-crispr-neurodegeneration-20260402)
Resolution criteria
Resolution requires: (1) off-target epigenomic profiling (ChIP-seq for H3K4me1, H3K27ac, ATAC-seq) in CRISPR-edited cells vs non-edited controls across >=3 different genomic loci, with off-target defined as >1% change in H3K27ac at any non-intended site; (2) long-term (>=6 months) in vivo epigenomic profiling in CRISPR-edited mouse models showing no significant increase in oncogenic or neurotoxic chromatin signatures; (3) comparative transcriptomics of edited cells at 1 month vs 6 months vs 12 months post-editing, showing no progressive oncogenic program activation. Short-term studies (<3 months) cannot resolve long-term safety.